Systemic Juvenile Idiopathic Arthritis Global Market Report 2025
상품코드:1889600
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
전신성 소아특발성관절염 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2024년 12억 8,000만 달러로 평가되었고, 2025년에는 13억 6,000만 달러에 달할 것으로 추정되며, CAGR 6.1%로 확대될 전망입니다. 지난 수년간의 성장은 초기 증상에 대한 인식 증가, 생물학적 제형 요법의 도입 증가, 조기 진단에 대한 중점 강화, 헬스케어 지출 증가, 소아 의료용 정부 시책 확대, 고급 진단 도구의 보급 확대로 인한 것으로 예측됩니다.
전신성 소아특발성관절염 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 17억 달러에 달할 것으로 예측되며, CAGR 5.7%로 성장할 전망입니다. 예측 기간의 성장 요인으로는 맞춤형 치료 접근법의 채택 확대, 간병인 및 헬스케어 제공업체의 의식 향상, 첨단 생물학적 요법의 보급 확대, 소아 의료 인프라 투자 증가, 조기 및 정확한 진단에 대한 주력 강화 등이 있습니다. 예측 기간 동안 예상되는 주요 동향은 표적 생물학적 요법의 개발, 실세계 데이터 통합, 사이토카인 표적 치료의 혁신, 환자 참여 도구의 진보, 복합 치료 프로토콜의 확립 등을 포함합니다.
자가면역 질환의 유병률 상승은 전신성 소아특발성관절염(sJIA) 시장의 성장을 이끌 것으로 예측됩니다. 자가면역 질환은 면역계가 실수로 건강한 조직을 공격함으로써 발생하며, 그 유병률 증가는 유전적 소인이나 면역계의 조절 이상과 관련되어 있습니다. 자가면역 질환의 광범위한 조직 손상의 기초가 되는 염증 경로와 면역 메커니즘의 해명에 특이적인 자가면역 질환인 전신성 소아특발성관절염은 중요한 지견을 제공합니다. 예를 들어, 호주 관절염 협회(Arthritis Australia)에 따르면, 2024년에는 남성 약 21만 2,136명, 여성 약 36만 2,137명이 관절 류마티스를 앓고 있는 것으로 추정되고, 2040년까지 남성 약 28만 40명, 여성 약 47만 9,828명으로, 이러한 sJIA를 포함한 자가면역 질환의 유병률 증가는 효과적인 치료법에 대한 수요를 견인하고 있습니다.
전신성 소아특발성관절염 시장의 기업은 치료 효과, 안전성, 환자 편의성을 높이기 위해 정맥내(IV) 제제를 포함한 혁신적인 치료법에 주력하고 있습니다. IV 제형은 약물을 신속하고 통제된 형태로 직접 혈류로 전달할 수 있어 보다 신속한 치료 효과의 실현을 지원합니다. 2025년 10월, 한국에 본사를 둔 바이오 의약품 기업 셀트리온사는 토실리주맙의 바이오시밀러인 정주 제제 'AVTOZMA'를 미국에서 발매했습니다. AVTOZMA는 전신성 소아특발성관절염(sJIA), 류마티스 관절염, 사이토카인 방출 증후군의 치료를 제공하며, 참조 제품인 액템라를 대체하는 비용 효율적인 선택이 됩니다. 정맥내 투여와 피하 투여 옵션을 모두 제공함으로써 AVTOZMA는 환자 접근성 향상, 임상의의 유연성 향상 및 맞춤 치료 계획을 지원합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 전신성 소아특발성관절염 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 전신성 소아특발성관절염 시장 : 성장률 분석
세계의 전신성 소아특발성관절염 시장 실적 : 규모 및 성장(2019-2024년)
세계의 전신성 소아특발성관절염 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 전신성 소아특발성관절염 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 전신성 소아특발성관절염 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
약물 치료
생물학적 제형
기타 치료
세계의 전신성 소아특발성관절염 시장 : 연령층별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
영유아
소아
사춘기
세계의 전신성 소아특발성관절염 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 전신성 소아특발성관절염 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
학술연구센터
기타 최종 사용자
세계의 전신성 소아특발성관절염 시장 : 약물 치료 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
비스테로이드성 항염증제
코르티코스테로이드
질환 수식성 항류마티스약
세계의 전신성 소아특발성관절염 시장 : 생물학적 제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
인터루킨-1 억제제
인터루킨-6 억제제
종양 괴사 인자 억제제
세계의 전신성 소아특발성관절염 시장 : 기타 치료 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
물리 치료
작업 치료
지지 치료
실험적 치료
제7장 지역별 및 국가별 분석
세계의 전신성 소아특발성관절염 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 전신성 소아특발성관절염 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
전신성 소아특발성관절염 시장 : 경쟁 구도
전신성 소아특발성관절염 시장 : 기업 프로파일
Johnson And Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
Novartis AG
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly And Company
Takeda Pharmaceutical Company Limited
Amgen Incorporated
Boehringer Ingelheim
Regeneron Pharmaceuticals Incorporated
Chugai Pharmaceutical Company Limited
Genentech Incorporated
Swedish Orphan Biovitrum Aktiebolag
Zydus Lifesciences Limited
Celltrion Incorporated
Mycenax Biotech Incorporated
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
전신성 소아특발성관절염 시장(2009년) : 새로운 기회를 제공하는 국가
전신성 소아특발성관절염 시장(2029년) : 새로운 기회를 제공하는 부문
전신성 소아특발성관절염 시장(2009년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Systemic juvenile idiopathic arthritis (SJIA) is a rare form of childhood arthritis that causes widespread inflammation throughout the body, not just in the joints. It is marked by recurring high fevers, a distinctive rash, and swelling or pain in multiple joints. Unlike other juvenile arthritis types, SJIA can also affect internal organs such as the liver, spleen, and heart. The exact cause remains unknown but is thought to be linked to an abnormal immune response.
The main treatment types for systemic juvenile idiopathic arthritis include drug treatment, biologics, and other therapeutic options. Drug treatment refers to the use of medications-such as biologics, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs)-to reduce inflammation, manage symptoms, and prevent joint damage in patients with SJIA. Treatment is provided across various age groups, including infants, children, and adolescents. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by multiple end users, including hospitals, specialty clinics, academic research centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The systemic juvenile idiopathic arthritis market research report is one of a series of new reports from The Business Research Company that provides systemic juvenile idiopathic arthritis market statistics, including systemic juvenile idiopathic arthritis industry global market size, regional shares, competitors with a systemic juvenile idiopathic arthritis market share, detailed systemic juvenile idiopathic arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic juvenile idiopathic arthritis industry. This systemic juvenile idiopathic arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The systemic juvenile idiopathic arthritis market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. Growth during the historic period can be attributed to increasing awareness of early symptoms, rising adoption of biologic therapies, greater emphasis on early diagnosis, increasing healthcare expenditure, expanding government initiatives for pediatric care, and wider availability of advanced diagnostic tools.
The systemic juvenile idiopathic arthritis market size is expected to see strong growth in the next few years. It will grow to $1.70 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. Growth in the forecast period can be attributed to the increasing adoption of personalized treatment approaches, rising awareness among caregivers and healthcare providers, greater availability of advanced biologic therapies, increasing investments in pediatric healthcare infrastructure, and a stronger focus on early and accurate diagnosis. Major trends expected in the forecast period include the development of targeted biologic therapies, integration of real-world data, innovations in cytokine-targeted treatments, advancements in patient engagement tools, and the creation of combination treatment protocols.
The rising prevalence of autoimmune disorders is expected to drive growth in the systemic juvenile idiopathic arthritis (sJIA) market. Autoimmune disorders occur when the immune system mistakenly attacks healthy tissues, and their increasing prevalence is linked to genetic susceptibility and immune system dysregulation. Systemic juvenile idiopathic arthritis, a distinct autoimmune condition, provides insights into the inflammatory pathways and immune mechanisms underlying widespread tissue damage in autoimmune diseases. For example, according to Arthritis Australia, an estimated 212,136 males and 362,137 females were projected to have rheumatoid arthritis in 2024, with numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. The growing prevalence of autoimmune disorders like sJIA is therefore driving demand for effective therapies.
Companies in the systemic juvenile idiopathic arthritis market are focusing on innovative therapies, including intravenous (IV) formulations, to enhance treatment efficacy, safety, and patient convenience. IV formulations allow rapid and controlled delivery of drugs directly into the bloodstream, supporting faster therapeutic effects. In October 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched AVTOZMA, a tocilizumab biosimilar IV formulation, in the United States. AVTOZMA offers treatment for sJIA, rheumatoid arthritis, and cytokine release syndrome, providing a cost-effective alternative to the reference product Actemra. By offering both IV and subcutaneous options, AVTOZMA improves patient access, enhances flexibility for clinicians, and supports personalized treatment regimens.
In April 2025, Organon & Co., a US pharmaceutical company, acquired Tofidence (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. This acquisition expanded Organon's U.S. immunology and arthritis portfolio, enabling broader access to multi-indication arthritis therapies and reinforcing the development of effective treatments for systemic juvenile idiopathic arthritis.
Major companies operating in the systemic juvenile idiopathic arthritis market are Johnson And Johnson, F. Hoffmann-La Roche Limited, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly And Company, Takeda Pharmaceutical Company Limited, Amgen Incorporated, Boehringer Ingelheim, Regeneron Pharmaceuticals Incorporated, Chugai Pharmaceutical Company Limited, Genentech Incorporated, Swedish Orphan Biovitrum Aktiebolag, Zydus Lifesciences Limited, Celltrion Incorporated, Mycenax Biotech Incorporated.
North America was the largest region in the systemic juvenile idiopathic arthritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in systemic juvenile idiopathic arthritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the systemic juvenile idiopathic arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The systemic juvenile idiopathic arthritis market consists of revenues earned by entities by providing services such as pharmaceutical treatments, clinical consultation services, hospital and outpatient care, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The systemic juvenile idiopathic arthritis market also includes sales of canakinumab, tocilizumab, methotrexate, corticosteroids, and nonsteroidal anti-inflammatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Systemic Juvenile Idiopathic Arthritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on systemic juvenile idiopathic arthritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for systemic juvenile idiopathic arthritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The systemic juvenile idiopathic arthritis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Drug Treatment; Biologics; Other Treatment Types
2) By Age Group: Infants; Children; Adolescents
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Academic Research Centers; Other End-Users
Subsegments:
1) By Drug Treatment: Nonsteroidal Anti-Inflammatory Drugs; Corticosteroids; Disease-Modifying Antirheumatic Drugs
3. Systemic Juvenile Idiopathic Arthritis Market Trends And Strategies
4. Systemic Juvenile Idiopathic Arthritis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Systemic Juvenile Idiopathic Arthritis Growth Analysis And Strategic Analysis Framework
5.1. Global Systemic Juvenile Idiopathic Arthritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Systemic Juvenile Idiopathic Arthritis Market Growth Rate Analysis
5.4. Global Systemic Juvenile Idiopathic Arthritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Systemic Juvenile Idiopathic Arthritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Systemic Juvenile Idiopathic Arthritis Total Addressable Market (TAM)
6.1. Global Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drug Treatment
Biologics
Other Treatment Types
6.2. Global Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infants
Childrens
Adolescents
6.3. Global Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Systemic Juvenile Idiopathic Arthritis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Academic Research Centers
Other End-Users
6.5. Global Systemic Juvenile Idiopathic Arthritis Market, Sub-Segmentation Of Drug Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Disease-Modifying Antirheumatic Drugs
6.6. Global Systemic Juvenile Idiopathic Arthritis Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin-1 Inhibitors
Interleukin-6 Inhibitors
Tumor Necrosis Factor Inhibitors
6.7. Global Systemic Juvenile Idiopathic Arthritis Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Physical Therapy
Occupational Therapy
Supportive Care
Experimental Therapies
7. Systemic Juvenile Idiopathic Arthritis Market Regional And Country Analysis
7.1. Global Systemic Juvenile Idiopathic Arthritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Systemic Juvenile Idiopathic Arthritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Systemic Juvenile Idiopathic Arthritis Market
9.1. China Systemic Juvenile Idiopathic Arthritis Market Overview
9.2. China Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Systemic Juvenile Idiopathic Arthritis Market
10.1. India Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Systemic Juvenile Idiopathic Arthritis Market
11.1. Japan Systemic Juvenile Idiopathic Arthritis Market Overview
11.2. Japan Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Systemic Juvenile Idiopathic Arthritis Market
12.1. Australia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Systemic Juvenile Idiopathic Arthritis Market
13.1. Indonesia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Systemic Juvenile Idiopathic Arthritis Market
14.1. South Korea Systemic Juvenile Idiopathic Arthritis Market Overview
14.2. South Korea Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Systemic Juvenile Idiopathic Arthritis Market
15.1. Western Europe Systemic Juvenile Idiopathic Arthritis Market Overview
15.2. Western Europe Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Systemic Juvenile Idiopathic Arthritis Market
16.1. UK Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Systemic Juvenile Idiopathic Arthritis Market
18.1. France Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Systemic Juvenile Idiopathic Arthritis Market
21.1. Eastern Europe Systemic Juvenile Idiopathic Arthritis Market Overview
21.2. Eastern Europe Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Systemic Juvenile Idiopathic Arthritis Market
22.1. Russia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Systemic Juvenile Idiopathic Arthritis Market
23.1. North America Systemic Juvenile Idiopathic Arthritis Market Overview
23.2. North America Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Systemic Juvenile Idiopathic Arthritis Market
24.1. USA Systemic Juvenile Idiopathic Arthritis Market Overview
24.2. USA Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Systemic Juvenile Idiopathic Arthritis Market
26.1. South America Systemic Juvenile Idiopathic Arthritis Market Overview
26.2. South America Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Systemic Juvenile Idiopathic Arthritis Market
27.1. Brazil Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Systemic Juvenile Idiopathic Arthritis Market
28.1. Middle East Systemic Juvenile Idiopathic Arthritis Market Overview
28.2. Middle East Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Systemic Juvenile Idiopathic Arthritis Market
29.1. Africa Systemic Juvenile Idiopathic Arthritis Market Overview
29.2. Africa Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Systemic Juvenile Idiopathic Arthritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Systemic Juvenile Idiopathic Arthritis Market Competitive Landscape And Company Profiles
